Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety of EFX in patients with metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2–F3). The study met its primary endpoint of ≥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) dose groups, compared to 20% for the placebo group. At Week 96, response rates for this endpoint increased to 75% (p<0.001) for 50 mg EFX and 46% (p=0.07) for 28 mg EFX, vs 24% for placebo.
一份最新的口頭報告將呈現HARMONY研究96周的數據,該研究評估了EFX對代謝紊亂相關的脂肪肝(MASH)和纖維化2-3期(F2-F3)患者的療效和安全性。該研究在50 mg EFX(41%,p
The study also met additional histology endpoints at week 96. Notably 36% (p<0.01) and 31% (p<0.01) of patients treated with 50 mg EFX and 28 mg EFX, respectively, had a 2-stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate of 3%.
該研究還在96周時達到了其他組織學終點。值得注意的是,分別接受50 mg EFX和28 mg EFX治療的患者有36%(p